Inovio and Collaborators Receive NIH Grantto Evaluate HIV Immunotherapy PENNVAX-GPs Abilityto Induce … – EconoTimes
|
Inovio and Collaborators Receive NIH Grantto Evaluate HIV Immunotherapy PENNVAX-GPs Abilityto Induce …
EconoTimes Development of Inovio’s PENNVAX-GP immunotherapy, which widely targets multiple major clades of HIV — providing global coverage — has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. In addition, Inovio and … |
|
Inovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce …
GlobeNewswire (press release) Development of Inovio’s PENNVAX-GP immunotherapy, which widely targets multiple major clades of HIV — providing global coverage — has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. In addition, Inovio and … |
|
Stem Cell Therapy May Reduce Lung Inflammation Associated with Cystic Fibrosis
Cystic Fibrosis News Today Stem cell therapy may reduce lung inflammation in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), according to preliminary results of a pre-clinical-trial study. The findings, presented at this year’s Lung Science Conference in … |
|
CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing
KULR-TV BASEL, Switzerland, March 28, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP) reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing … |
UConn Daily Campus |
UConn Professor conducting T and stem cell research to treat cancer, autoimmune disease
UConn Daily Campus “The second area of my research is using stem cell technology to prevent and treat autoimmune disease,” Lai said. The thymus, an organ of the immune system, is the primary organ that naturally produces T cells for the body. “Thymic epithelial cells … |
Insider Financial |
US Stem Cell Inc (OTCMKTS:USRM) Keeps Rising, Here’s Why
Insider Financial Following another piece published by us, US Stem Cell Inc (OTCMKTS:USRM) does not stop climbing. It even jumped almost 10% yesterday with no news. We wanted to find communications today about the company to explain this behavior, but could not … |